Pfizer Reports $14.7 Billion Revenue in Q2 2025, 10% Increase Year-Over-Year

Pfizer Inc. reported a total revenue of $14.7 billion for the second quarter of 2025, marking a 10% increase from $13.3 billion in the same period last year. This growth was primarily driven by strong performances from key products such as the Vyndaqel family, Comirnaty, and Paxlovid, despite facing challenges from increased manufacturer discounts due to the Inflation Reduction Act (IRA) Medicare Part D Redesign. For the first six months of 2025, total revenues reached $28.4 billion, a slight increase of 1% compared to $28.2 billion in the first half of 2024. The operational increase of $439 million was partially offset by unfavorable foreign exchange impacts.

In terms of profitability, Pfizer's income from continuing operations before taxes was $3.0 billion in the second quarter of 2025, a significant recovery from a loss of $103 million in the same quarter of 2024. The increase in profitability was attributed to higher revenues, reduced restructuring charges, and net gains on equity securities. For the first half of 2025, income from continuing operations rose to $5.8 billion, up from $3.3 billion in the prior year, driven by lower selling, administrative, and research expenses.

Strategically, Pfizer has been focusing on cost realignment and productivity improvements through various initiatives, including a multi-year cost realignment program expected to yield approximately $5.7 billion in savings by 2027. The company also announced an exclusive global in-licensing agreement with 3SBio for the development of SSGJ-707, a bispecific antibody, which includes an upfront payment of $1.25 billion and potential milestone payments totaling up to $4.8 billion.

Operationally, Pfizer's total assets decreased to $206.1 billion as of June 29, 2025, down from $213.4 billion at the end of 2024. The company reported a headcount of approximately 90,000 employees, reflecting ongoing adjustments in its workforce to align with strategic goals. The company continues to monitor market conditions and regulatory changes, particularly those related to drug pricing and access, which could impact future revenues and profitability.

Looking ahead, Pfizer anticipates continued revenue growth from its key products, although it expects challenges from pricing pressures and potential declines in sales of COVID-19 related products as the pandemic evolves. The company remains committed to enhancing its research and development capabilities and optimizing its capital allocation to support long-term growth.